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Bovine parainfluenza virus type 3 (bPIV3) is under development as a live virus vaccine vector. The RNA genome of a
recombinant bPIV3 harbored four nucleotide changes, one of which resulted in a mutation of the viral polymerase (A. A. Haller
et al., 2000, J. Virol. 74, 11626–11635). The contribution of this conservative amino acid substitution (I1103V) in the polymerase
to the temperature-sensitive and attenuation phenotypes of r-bPIV3 was investigated by creating a new virus, r-bPIV3(I), that
expressed the wild-type polymerase. r-bPIV3(I) was not temperature-sensitive for growth in vitro and the replication of
r-bPIV3(I) was no longer restricted in hamsters. The effect of the amino acid substitution in the polymerase was also studied
in a chimeric bovine/human PIV3, a virus that displayed temperature-sensitive and attenuated phenotypes (A. A. Haller et al.,
2000, J. Virol. 74, 11626–11635). It was not clear whether these defects were due to the impaired polymerase or the
replacement of the bPIV3 surface glycoproteins with those of hPIV3. The results showed that the altered polymerase was
indeed responsible for the temperature-sensitive phenotype of bovine/human PIV3 but did not appear to play a role in the
attenuation phenotype. © 2001 Academic PressKey Words: bovine parainfluenza type 3; polymerase mutation; temperature sensitivity; attenuation; live virus vaccine
vector.INTRODUCTION
The paramyxovirus family comprised a great number
of human pathogens such as human parainfluenza virus
types 1, 2, and 3 (hPIV1, 2, 3), measles, mumps, and
human respiratory syncytial virus (hRSV) (Dolin, 1994;
Welliver et al., 1986; Johnson and Goodpasture, 1935;
Griffin and Bellini, 1996). All of these viruses cause seri-
ous respiratory illnesses in young infants and the elderly,
often resulting in hospitalization or death (Falsey et al.,
1995). Attempts to create effective vaccines to protect
from these infectious agents have been ongoing for at
least three decades. Live, attenuated viruses are prefer-
able to killed virus or viral subunit preparations for vac-
cines because live viruses can stimulate a balanced
humoral and cellular immune response at a mucosal
location (Crowe, 1998).
Bovine parainfluenza virus type 3 (bPIV3) (Kansas/
15626/84) was isolated from cattle and has gained in-
creased importance in recent years as a vaccine candi-
date for hPIV3, an infectious agent causing acute respi-
ratory disease in infants. Bovine and human PIV3 are
antigenically related and animals immunized with bPIV3
were protected from infection by hPIV3 (van Wyke Coel-
ingh et al., 1987; Karron et al., 1996). Clinical studies
showed that infants as young as 2 months old immu-1 To whom correspondence and reprint requests should be ad-
ressed. Fax: 650-919-6611. E-mail: ahaller@aviron.com.
0042-6822/01 $35.00
Copyright © 2001 by Academic Press
All rights of reproduction in any form reserved.
342nized with bPIV3 exhibited protective immunity to hPIV3
(Karron et al., 1996). Thus, although replication of bPIV3
in humans is somewhat restricted, it elicits an immune
response. The precise genetic determinants of bPIV3
that result in host restriction in humans are not yet
known (Bailly et al., 2000; Schmidt et al., 2000). Due to the
promising results obtained from the clinical trials evalu-
ating bPIV3 as a hPIV3 vaccine candidate, bPIV3 was
further developed as a virus vaccine vector to deliver
foreign viral antigens (Haller et al., 2000).
bPIV3 is an enveloped, negative-sense, single-strand
RNA virus. The bPIV3 genome is an uncapped RNA of
15,456 nucleotides (Haller et al., 2000). The 39 half of the
viral genome encodes the nucleoprotein (NP) that en-
capsidates the viral RNA and the phosphoprotein (P),
which is associated with the functional ribonucleoprotein
(RNP) (Collins et al., 1996). In addition, the P open read-
ing frame encodes three smaller proteins, C, D, and V.
The functions of these bPIV3 proteins are not known.
Results from other paramyxoviruses suggest that the C
protein may inhibit the action of interferon (Garcin et al.,
2000) and that the V protein slows progression of the cell
cycle (Lin and Lamb, 2000). The genes encoding the
matrix (M) protein, an integral component of virion parti-
cle formation, and the fusion (F) and hemagglutinin-
neuraminidase (HN) proteins are also located on the 39
half of the viral RNA (Collins et al., 1996). The majority of
the 59 half of the viral RNA encodes the 2233 amino acid
large (L) protein. The L protein is a multifunctional protein
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functions as the RNA-dependent RNA polymerase, which
has a role in RNA transcription, RNA replication, and
RNA polyadenylation (Collins et al., 1996). The template
for viral RNA synthesis is the NP encapsidated genomic
RNA. Transcription starts at the 39 end of the genomic
RNA. mRNAs are synthesized according to the viral gene
order such that a transcription gradient is formed from
the 39 to the 59 end of the genome. Genome replication
directed by the viral polymerase yields full-length posi-
tive and subsequently negative-strand genomic RNAs
that are encapsidated with NP protein to form viral nu-
cleocapsids (Lamb and Kolakofsky, 1996). Alignment of a
number of viral polymerase genes derived from related
paramyxoviruses, including Sendai virus, Newcastle dis-
ease virus, and rhabdoviruses such as rabies and vesic-
ular stomatitis virus, showed that the viral polymerases
contain six colinear and highly conserved motifs impor-
tant for the catalytic activity of the protein. Three of these
conserved motifs are present in other RNA-dependent
RNA polymerases and RNA-dependent DNA poly-
merases. These motifs can be modeled spatially to form
the catalytic as well as the RNA template binding sites
(Poch et al., 1990; Stec et al., 1991).
An infectious cDNA of bPIV3 was constructed at Avi-
ron and infectious recombinant virus was rescued by
reverse genetics (Haller et al., 2000). The linear gene
organization of the 15,456-nucleotides-long RNA genome
of r-bPIV3 is shown in Fig. 1. Upon sequencing of the
bPIV3 cDNA, four sequence changes were identified that
differed from the sequence of the biologically derived
FIG. 1. A schematic representation of the recombinant bPIV3 geno
egions. The solid boxes between genes indicate the conserved gene
enetic marker, an XhoI restriction enzyme site in the F gene, is indica
ecombinant viral RNA (in the F gene at nt 6460 and 6463, in the L gene
t 11,919 to 11,969 encompassing the point mutation of r-bPIV3, bPIV3, a
s shown in bold print and the substituted amino acid of the polymerabPIV3 (Haller et al., 2000). Two of these point mutations
nucleotides 6460 and 6463) were genetically engi-neered to generate a genomic marker in the viral RNA,
an XhoI restriction enzyme site in the F gene (Fig. 1).
Neither of these nucleotide changes resulted in an
amino acid substitution in the F protein. The third nucle-
otide change was located in the noncoding region of the
L gene at position nucleotide 15,354 (Fig. 1). This nucle-
otide change was not expected to yield an altered virus
phenotype as it did not change the consensus gene stop
sequences of the L gene or the trailer regions of the
bPIV3 genome. The fourth single nucleotide alteration
was identified in the L gene of r-bPIV3 at position 11,946
in the viral polymerase (Fig. 1). This nucleotide change
resulted in a single amino acid substitution, an isoleu-
cine to a valine at amino acid 1103, in the L protein of
r-bPIV3 (Fig. 1). In this paper, we examine the impact of
this amino acid change on the replication of r-bPIV3 in
vitro and in hamsters. This change confers a tempera-
ture-sensitive and attenuated phenotype to r-bPIV3 that
can be exploited in future vectored vaccine designs.
RESULTS
Minigenome CAT expression by wild-type and mutant
bPIV3 polymerases at different temperatures
The r-bPIV3 described previously had a temperature-
sensitive phenotype in vitro (Haller et al., 2000). A CAT
reporter assay was used to determine whether the single
amino acid substitution (I1103V) present in the L poly-
merase of r-bPIV3 had an impact on viral RNA synthesis.
Both the wt (I1103) and mutant (V1103) forms of L poly-
merase were inserted in an expression plasmid (L/
e bPIV3 genome is flanked by untranslated leader (le) and trailer (tr)
nd gene start sequences of bPIV3 required for viral transcription. The
e asterisks indicate the location of the four sequence changes in the
1,946 and 15,354). The coding sequence of the polymerase gene from
IV3(I) is shown in detail. The single nucleotide that is altered in r-bPIV3
oxed in.me. Th
stop a
ted. Th
at nt 1pCITE). DNA sequencing of the corrected L gene con-
firmed that no additional nucleotide alterations were
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344 HALLER ET AL.introduced during the cloning process. MVA-T7-infected
HeLa cells were transfected with plasmids encoding the
T7 promoter expressed bPIV3 P, NP, and wt (I1103) or
mutant (V1103) L proteins along with the bPIV3/CAT mini-
genome plasmid, and the cells were incubated at 33, 37,
or 39°C. The CAT protein produced was quantified by
ELISA.
Different amounts of the wild-type L (I1103) expression
plasmid were transfected with constant amounts of NP,
P, and minigenome to determine the range of CAT pro-
duction in HeLa cells (Fig. 2A). At 200 to 250 ng of
wild-type L (I1103), a high level of minigenome transcrip-
tion and replication was obtained as measured by the
amount of CAT protein produced. The amount of CAT
FIG. 2. BPIV3 CAT minigenome assay using wild-type (I1103) and
mutant (V1103) L genes. (A) Transient transfections of increasing con-
centrations of wild-type (I1103) L plasmid in the minigenome assay
system is described in detail under Materials and Methods. Increasing
amounts of wild-type L plasmid (from 50–250 ng DNA) were transfected
together with NP, P, and bPIV3/CAT gene plasmids into HeLa cells
infected with MVA-T7. Forty hours posttransfection, the cells were
harvested and the amount of CAT protein produced was determined by
CAT ELISA. (B) The amount of CAT protein produced in the minigenome
assay system at 33, 37, or 39°C in the presence of 200 ng of wild-type
(WT) (I1103) or mutant (M) (V1103) L gene plasmids.protein produced at 250 ng of wild-type L plasmid (I1103)
was arbitrarily set at 100%. CAT protein was not observed
f
dwhen bPIV3/CAT was transfected alone or in transfec-
tions in which the L, NP, or P plasmids were omitted
(data not shown). In the presence of similar amounts of
the mutant L gene (V1103) plasmid, approximately 30% of
wild-type activity at 33, 37 and 39°C was obtained (Fig.
2B). The amounts of CAT protein produced using the
wild-type L plasmid (I1103) were arbitrarily set at 100%.
The CAT protein production by the mutant bPIV3 poly-
merase relative to the wild-type bPIV3 polymerase re-
mained the same with increasing temperature (Fig. 2B).
The mutant L (V1103) enzyme was less active than wt L
(I1103) at all temperatures tested. The mutant bPIV3
polymerase exhibited a temperature-independent defect
in RNA synthesis in vitro, in contrast to the temperature-
sensitive defect observed in the replication of r-bPIV3 in
tissue culture. The temperature-sensitive defect ob-
served in the r-bPIV3 virus may be expressed only in the
context of other viral or cellular components involved in
the viral life cycle.
Replication of r-bPIV3(I) is not temperature-sensitive
in tissue culture
The wt L gene was introduced into the full-length
bPIV3 cDNA and r-bPIV3(I) virus was recovered by re-
verse genetics. r-bPIV3(I) still harbored the nucleotide
changes specifying an XhoI restriction enzyme site in the
F gene and the single nucleotide change at 15,354 in the
L gene untranslated region. To determine whether
r-bPIV3(I) exhibited a temperature-sensitive phenotype,
plaque formation on Vero cells at permissive and restric-
tive temperatures was tested (Table 1). Cells infected
with bPIV3, r-bPIV3, and r-bPIV3(I) were incubated at 37,
38, 39, and 40°C for 4 days and plaques were visualized
by immunoperoxidase staining with bPIV3 goat poly-
clonal antiserum. The results showed that r-bPIV3 was
temperature-sensitive at 39°C as reported previously
(Haller et al., 2000). The titer of r-bPIV3 decreased by
approximately 1 log10 at 39°C and was reduced by .3
log10 at 40°C compared to the biologically derived bPIV3
Table 1). The biologically derived bPIV3 did not change
ignificantly in titer with increasing temperature (Table
). Plaque formation by r-bPIV3(I) was similar to wild-type
irus at all temperatures (Table 1). This data demon-
trated that the V1103 in the L protein of r-bPIV3 was the
ole determinant of the temperature-sensitive phenotype
f r-bPIV3 and that the other nucleotide changes present
n the r-bPIV3 genome did not contribute to this pheno-
ype.
Multicycle replication of bPIV3, r-bPIV3, and r-bPIV3(I)
as also evaluated in Vero cells (Fig. 3). Briefly, subcon-
luent Vero cells were infected at an m.o.i. of 0.01 and
ncubated at 37, 39, and 40°C. Infected cells and super-
atants were harvested at 0, 24, 48, 72, and 96 h postin-ection and the amount of virus at each time point was
etermined by TCID50 assays.
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345BOVINE PARAINFLUENZA VIRUS TYPE 3 POLYMERASE MUTATIONAt 37°C, all three viruses replicated to similar levels
with similar kinetics (Fig. 3A). All three viruses reached
peak titers of 8 log10 TCID50/ml by 48 h postinfection and
sustained these titers up to 96 h postinfection at 37°C.
T
Determination of the Shut-Off Tempera
Virus
Mean virus titer (log10 PFU/m
37 38
bPIV3 9.1 8.9
r-bPIV3 8.6 8.3
r-bPIV3(I) 8.9 8.9
Bovine/human PIV3(I) 7.5 7.7
hPIV3 7.7 7.8
a Plaques were enumerated by immunoperoxidase staining after inc
FIG. 3. Multicycle growth curves of bPIV3, r-bPIV3, and r-bPIV3(I)
were carried out at 37°C (A), 39°C (B), and 40°C (C) in Vero cells. Timel
b
points were collected at 0, 24, 48, 72, and 96 h postinfection. The virus
samples were analyzed for virus titers by TCID50 assays in Vero cells.r-bPIV3(I) and bPIV3 yielded similar titers at 39°C (Fig.
3B). Their peak titers were 8.1 and 8.6 log10 TCID50/ml at
48 h postinfection, respectively. However, at 39°C,
r-bPIV3 displayed a delayed onset of replication and a
reduced peak titer (7.0 log10 TCID50/ml) compared to
bPIV3 (Fig. 3B); this virus was temperature-sensitive as
described previously (Fig. 3B) (Haller et al., 2000). All
viruses had reduced titers at 40°C; however, the temper-
ature-sensitive phenotype of r-bPIV3 was accentuated.
r-bPIV3 displayed dramatic 7 and 5 log10 reductions in
irus titers at 40°C compared to its peak titers at 37 and
9°C, respectively (Figs. 3A, 3B, and 3C). The biologically
erived bPIV3 was also reduced by 2.3 log10 at 40°C
compared to its peak titer at 37°C (Figs. 3A and 3C).
r-bPIV3(I) replicated as efficiently as the biologically de-
rived bPIV3 at 40°C, reaching peak titers at 72 h postin-
fection. This data further substantiated that a single
amino acid change in the L protein at position 1103 is the
major determinant of the temperature-sensitive pheno-
type observed in r-bPIV3.
Replication of r-bPIV3(I) is not attenuated in Syrian
golden hamsters
Syrian golden hamsters have been shown to be per-
missive for infection by hPIV3 and bPIV3, displaying
efficient replication in the lower and upper respiratory
tracts (Durbin et al., 1999; Haller et al., 2000). To examine
whether amino acid 1103 in the polymerase protein had
an effect on the attenuation phenotype, we tested the
replication of bPIV3, r-bPIV3, and r-bPIV3(I) in Syrian
golden hamsters (Table 2). Briefly, hamsters were inoc-
ulated intranasally with 5 3 105 PFU of bPIV3, r-bPIV3, or
-bPIV3(I). Four days postinfection the animals were sac-
ificed. The lungs and nasal turbinates were harvested
nd virus titers were determined by TCID50 assays using
Vero cells. r-bPIV3(I) replicated to 5.5 and 5.4 log10
TCID50/g tissue in the nasal turbinates and lungs of
amsters, respectively, which were similar to the levels
bserved for the biologically derived bPIV3. r-bPIV3 rep-
f r-bPIV3(I) and Bovine/Human PIV3(I)
dicated temperaturea (°C)
Temperature-sensitive
phenotype39 40
8.8 8.4 2
6.8 5.3 1
8.5 8.5 2
7.5 7.6 2
7.5 7.6 2
for 4 days at the indicated temperature.ABLE 1
ture o
l) at inicated to 5.0 log10 TCID50/g tissue in the nasal turbinates
ut showed a 1.5 log10 decrease in titer in the lungs
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346 HALLER ET AL.compared to bPIV3. These results demonstrated that the
single amino acid substitution (I1103V) in the r-bPIV3
polymerase specified not only the temperature-sensitive
phenotype but also the attenuation phenotype of r-bPIV3.
Although r-bPIV3 was attenuated weakly, animals immu-
nized with r-bPIV3 were still protected completely from
challenge with hPIV3 (Haller et al., 2000).
Effect of the polymerase mutation on a chimeric
bovine/human PIV3
We previously described the phenotypes of a chimeric
bovine/human PIV3(1103V) in which the bPIV3 F and HN
genes were replaced with those of hPIV3. Bovine/human
PIV3 displayed a shut-off temperature of 39.5°C and was
restricted by 1.5 log10 TCID50/g tissue for replication in the
ungs of hamsters (Haller et al., 2000). To determine
whether the observed phenotypes of bovine/human PIV3
were caused by the polymerase mutation (1103V) and/or
the substitution of the bPIV3 surface glycoprotein genes
with those of hPIV3, a recombinant virus, bovine/human
PIV3(I) containing 1103I and the hPIV3 F and HN genes
was constructed and tested for temperature-sensitivity in
tissue culture and replication in hamsters. The results
showed that bovine/human PIV3(I), like its parents,
bPIV3(I) and hPIV3, did not display any significant de-
crease in virus titers at temperatures as high as 40°C
(Table 1). Bovine/human PIV3(I) was also evaluated for
replication in the lower and upper respiratory tracts of
Syrian golden hamsters (Table 2). Bovine/human PIV3(I)
replicated to levels similar to its hPIV3 parent in the
nasal turbinates (4.9 log10 TCID50/g tissue). However,
there was a 0.9 log10 TCID50 unit reduction in virus titer of
ovine/human PIV3(I) in the lungs of hamsters compared
o hPIV3 or r-bPIV3(I). These data show that although the
olymerase mutation (I1103V) was responsible for the
TABLE 2
Replication of bPIV3, r-bPIV3, r-bPIV3(I), hPIV3, and Bovine/Human
PIV3(I) in the Upper and Lower Respiratory Tract of Hamsters
Virusa
Mean virus titer
on day 4 postinfection
(log10 TCID50/g tissue 6 S.E.)
b
Nasal turbinates Lungs
bPIV3 5.3 6 0.3 5.3 6 0.2
r-bPIV3 5.0 6 0.3 3.5 6 0.2
r-bPIV3(I) 5.5 6 0.2 5.4 6 0.2
hPIV3 4.9 6 0.2 5.4 6 0.2
Bovine/human PIV3(I) 4.9 6 0.2 4.5 6 0.2
a Groups of four hamster were inoculated intranasally with 5 3 105
PFU of indicated virus.
b Standard error.emperature-sensitive phenotype observed for bovine/
uman PIV3, it did not specify the restricted replication ofovine/human PIV3 in the lower respiratory tract of ham-
ters. The replacement of the bovine surface glycopro-
ein genes with those of hPIV3, a closely related virus,
esulted in attenuated replication in vivo.
DISCUSSION
Our studies showed that a single nucleotide alteration
n the polymerase gene of bPIV3 resulted in a recombi-
ant virus that displayed a temperature-sensitive pheno-
ype as well as restricted replication in the lower respi-
atory tract of hamsters. Both wild-type (I1103) and mu-
ant (V1103) forms of the L polymerase were examined
or activity and function in the bPIV3 minigenome repli-
ation assay. The results obtained from this assay
howed that indeed the mutant L gene displayed a three-
o fourfold reduction in RNA synthesis, according to the
evels of CAT protein produced, compared to the wild-
ype L gene. The observation that the defect in the L
rotein was not exacerbated by elevated temperatures
as in contrast to the temperature-sensitivity observed
or r-bPIV3 growth in Vero cells. The temperature-inde-
endent defect in the L protein observed in vitro was
artially suppressed in the virus where the defect man-
fested itself only at high temperatures.
A recombinant virus, r-bPIV3(I) with the corrected poly-
erase gene, was recovered. r-bPIV3(I) differed from
-bPIV3 only at the amino acid 1103 in the L gene. The
ther three nucleotide alterations present in the F gene
nd the untranslated region of the L gene were still
resent in r-bPIV3(I). r-bPIV3(I) did not express a temper-
ture-sensitive replication phenotype in tissue culture.
-bPIV3(I) showed the same plaque-forming efficiency as
he biologically derived bPIV3 at 37, 38, 39, and 40°C. In
ulticycle growth curves, r-bPIV3(I) and bPIV3 displayed
imilar kinetics of virus replication. Both viruses reached
eak titers at the same time points and replication was
omparable at all temperatures tested. The ability of
-bPIV3(I) to replicate in the upper and lower respiratory
racts of Syrian golden hamsters was similar to the bio-
ogically derived bPIV3. Thus, unlike r-bPIV3, r-bPIV3(I)
as not restricted for replication in hamsters.
Sequence alignment of the polymerase genes of a
umber of parainfluenza viruses was performed to ex-
mine the degree of conservation of the altered amino
cid residue at position 1103 in the L protein and the
egion surrounding it (Fig. 4). Interestingly, amino acid
103 was located in a 20 amino acid stretch of the
arainfluenza polymerase gene that was highly con-
erved among bPIV3, hPIV3, hPIV1, and Sendai virus,
lbeit this region is not part of the four conserved poly-
erase motifs A, B, C, or D (Poch et al., 1990). The amino
acid at position 1103 of these naturally occurring isolates
was either isoleucine (bPIV3, hPIV3) or leucine (hPIV1,
Sendai). A valine (r-bPIV3) was found at a similar position
in hPIV2 and mumps virus; however, the overall similarity
g all fiv
347BOVINE PARAINFLUENZA VIRUS TYPE 3 POLYMERASE MUTATIONamong these viruses is very limited. It is interesting to
speculate whether a change of valine to isoleucine at
this position in hPIV2 and mumps could result in atten-
uation of these viruses. Importation of temperature-sen-
sitivity markers has been successfully demonstrated
with parainfluenza viruses (hPIV3, Sendai virus) and a
pneumovirus (hRSV) (Feller et al., 2000; Skiadopoulos et
al., 1999). The apparent prerequisite of isoleucine or
leucine at 1103 is interesting, since isoleucine, leucine,
and valine have similar side chains differing only by a
single methyl group. However, this conservative substi-
tution was sufficient to confer dramatic attenuation on
r-bPIV3 replication in vitro and in vivo. Similar effects on
virus replication upon conservative amino acid substitu-
tions have been observed previously. For example, a
leucine to isoleucine substitution in the Sendai virus
polymerase at position 1558 exerted a dramatic effect on
virus replication (Feller et al., 2000). This amino acid
substitution did not affect viral transcription at the per-
missive temperature (33°C), but reduced transcription by
50% at 39.6°C. In vitro replication activity of the hPIV1
polymerase was reduced by 85% at the permissive tem-
perature. Surprisingly, the replication activity in tissue
culture was better than wild-type L at the permissive
temperature, but decreased rapidly at 37°C and was
inactive at 39.6°C (Feller et al., 2000). These results
underscore the difficulty of predicting the outcome of a
change in virus phenotype even in cases where the
amino acid substitution is chemically conservative.
The region of the r-bPIV3 L protein harboring the
FIG. 4. Comparison of polymerase genes among selected paramy
observed for r-bPIV3 compared to the wild-type sequence of bPIV3, h
conserved polymerase motifs (Poch et al., 1990; Stec et al., 1991). The th
of cp45 hPIV3 responsible for its temperature-sensitive phenotype are s
of this region of the L protein in r-bPIV3, bPIV3, hPIV3, hPIV1, and Senda
AAB48690, P27566). The amino acid residues that are conserved amon
in bold print.substituted amino acid was also compared to the loca-
tion of the mutations found in cp45 hPIV3 that are re-sponsible for its temperature-sensitive and attenuation
phenotype (Fig. 4). These three amino acid substitutions,
Y942H, L992F, T1558I, in the L protein of hPIV3 have
been shown to result in temperature-sensitive and atten-
uation phenotypes when present alone or in combination
(Skiadopoulos et al., 1998). None of the three point mu-
tations present in cp45 hPIV3 were close in primary
sequence to the I1103V change found in r-bPIV3. In the
linear context of the polymerase protein, the I1103V
change of r-bPIV3 was not close to any of the tempera-
ture-sensitivity markers in cp45 hPIV3. However, the spa-
tial relationships of this mutation to those present in
cp45 hPIV3 remain to be seen.
The polymerase mutation studied in this report also
conferred the temperature-sensitive phenotype of bo-
vine/human PIV3 in tissue culture, a chimeric virus de-
scribed previously (Haller et al., 2000). The restoration of
the wild-type sequence in the polymerase protein in
bovine/human PIV3(I) resulted in a non-temperature-sen-
sitive virus. Thus the introduction of the hPIV3 F and HN
genes alone did not result in an observable phenotype in
vitro. In contrast, bovine/human PIV3(I) still displayed
restricted replication in the lower respiratory tract of
hamsters. The impaired virus replication in vivo is likely
due to the introduction of the hPIV3 F and HN surface
glycoproteins that display 77 and 80% amino acid iden-
tities, respectively. Despite the high degree of similarity
in the amino acid sequences of the bovine and human
PIV3 surface glycoproteins, it appears that these pro-
teins are not completely interchangeable, resulting in an
es. The diagram shows the location of the amino acid substitution
PIV1, and Sendai virus. The four shaded boxes (A, B, C, D) indicate
ino acid changes, Y942H, L992F, and T1558I, present in the polymerase
The conserved region harboring the I1103V substitution and alignment
is shown (GenBank Accession Nos. NC002161, BAA32575, AAD23456,
e viruses are underlined. The valine 1103 present in r-bPIV3 is shownxovirus
PIV3, h
ree am
hown.
i virusobservable replication defect in vivo for bovine/human
PIV3(I).
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348 HALLER ET AL.In summary, we have identified a mutation in the bo-
vine parainfluenza virus polymerase that confers replica-
tion defects in vitro and in vivo. The polymerase mutation
I1103V) can be used to modulate the expression levels
f genes introduced in bPIV3. In cases where low levels
f expression are required, the r-bPIV3 vector can be
mployed. However, when higher levels of foreign pro-
ein are required, r-bPIV3(I) can be used instead. The
odulation of expression levels of the gene of interest
ay be advantageous for a virus vaccine vector depend-
ng on its application.
MATERIALS AND METHODS
iruses and cells
The bPIV3 (Kansas/15626/84), r-bPIV3, r-bPIV3(I),
PIV3 (Washington/478/85/57), and bovine/human
IV3(I) were grown in Vero cells in Opti-MEM medium
Gibco/BRL) containing antibiotics. The modified vac-
inia virus Ankara (MVA-T7), which expresses the phage
7 RNA polymerase (a gift from B. Moss), was grown in
hicken embryonic kidney cells (SPAFAS) (Wyatt et al.,
1995). Vero and HeLa cells were maintained in MEM
media (JRH Biosciences) supplemented with 10% fetal
bovine serum (FBS), 2 mM L-glutamine, nonessential
amino acids, and antibiotics.
Construction of the pbPIV3/CAT minireplicon
The pbPIV3/CAT minireplicon was constructed to con-
tain the antisense CAT gene flanked by the bPIV3 leader
linked to the hepatitis delta ribozyme (RZ) and T7 poly-
merase termination (T7T) signals. The bPIV3 trailer se-
quences were preceded by the T7 RNA polymerase
promoter. The DNA fragment containing the T7T, the RZ,
and the bPIV3 leader region of pbPIV3/CAT was pro-
duced by two overlapping PCR fragments using two
pairs of primers encoding a KpnI restriction enzyme site
and an XbaI site, respectively. The T7T/RBZ fragment
was amplified from pRSV/CAT, the RSV minigenome
plasmid (H. Jin, personal communication), and the bPIV3
leader region was amplified by PCR from the bPIV3
cDNA (Haller et al., 2000). These two PCR fragments
ontained overlapping sequences and were ligated by
nnealing/extension using limited cycles of PCR. The
CR product was cleaved with KpnI and XbaI and intro-
uced into the pRSV/CAT plasmid cut with KpnI and XbaI,
hereby replacing the T7T/RZ/RSV leader in pRSV/CAT.
he DNA fragment encoding the T7 RNA polymerase
romoter and the bPIV3 trailer region was amplified
sing two oligos complementary to the bPIV3 trailer
egion encoding a PstI restriction enzyme site or the T7
NA polymerase promoter encoding a HindIII restriction
nzyme site. The PCR product was digested with PstI
nd HindIII and used to replace the complementaryragment in the pRSV/CAT plasmid to yield the pbPIV3/
AT minireplicon plasmid.onstruction of the full-length r-bPIV3(I) and bovine/
uman PIV3(I) cDNAs
Employing the QuikChange mutagenesis kit (Strat-
gene), the single G residue at nucleotide position 11,946
n the r-bPIV3 L gene was changed to an A residue in the
lasmid L/pCITE described previously (Haller et al.,
000). The nucleotide change was confirmed by DNA
equencing. The altered L/pCITE plasmid was then di-
ested with restriction enzymes SacI and PacI to liberate
a 2.5-kb DNA fragment harboring the single nucleotide
change. This DNA fragment was then introduced into two
previously described plasmids, bPIV3/N/S and the plas-
mid containing the full-length bovine/human PIV3 cDNA,
cleaved with SacI and PacI. The L gene of the full-length
plasmids r-bPIV3(I) and bovine/human PIV3(I) were se-
quenced to verify the presence of the single nucleotide
change.
Transfection of full-length r-bPIV3(I) and
bovine/human PIV3(I) cDNA plasmids and preparation
of recombinant virus stocks
HeLa cells (80% confluent) were infected with modified
vaccinia virus Ankara (MVA-T7) at an m.o.i. of 4. One hour
postinfection, the full-length r-bPIV3(I) cDNA plasmid (4
mg) or the bovine/human PIV3(I) cDNA plasmid were
transfected into the MVA-T7-infected HeLa cells together
with the NP/pCITE (0.4 mg), P/pCITE (0.4 mg), and
L/pCITE (0.2 mg) expression plasmids in the presence of
9 ml LipofecTACE (Gibco/BRL) in 200 ml Opti-MEM
(Gibco/BRL). Forty-eight hours posttransfection, the pas-
sage 0 (P0) cells and media were harvested together and
subjected to one freeze-thaw cycle. The resulting P0 cell
lysate was then used to infect fresh Vero cell monolayers
in the presence of 40 mg/ml 1-b-D-arabinofuranosylcy-
tosine (ara C), a replication inhibitor of vaccinia virus, to
generate a P1 virus stock. The media and cells from this
infection cycle were harvested and freeze-thawed once,
and the presence of bPIV3 infection was confirmed by
immunostaining of virus plaques using bPIV3-specific
antiserum (VMRD) or hPIV3-specific antiserum (Chemi-
Con). Following two cycles of plaque purification in Vero
cells, high titer P2 (passage 2) virus stock was prepared
in Vero cells and stored at 280°C.
Genotyping of r-bPIV3(I) and bovine/human PIV3(I)
Viral RNA of r-bPIV3(I) or bovine/human PIV3(I) was
isolated from infected Vero cells using RNA STAT-50 LS
Reagent (Tel-Test, Inc.). To verify the genotypes of
r-bPIV3(I) or bovine/human PIV3(I), viral cDNA of
r-bPIV3(I) starting at nt 4500 was prepared using Super-
script Reverse Transcriptase (Gibco/BRL). DNA frag-
ments encompassing the region from nt 11,000 to nt
12,700 were amplified by PCR, resulting in a 1.7-kb PCR
product. The PCR products were sequenced to confirm
b
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349BOVINE PARAINFLUENZA VIRUS TYPE 3 POLYMERASE MUTATIONthe presence of the single nucleotide change in the viral
polymerase gene. The presence of the hPIV3 F and HN
genes of bovine/human PIV3(I) was also verified by se-
quencing of the RT-PCR products as described previ-
ously (Haller et al., 2000).
bPIV3 minigenome assay
Subconfluent HeLa cells were infected with MVA-T7 at
an m.o.i. of 5 PFU/cell (Wyatt et al., 1995). The infected
cells were cotransfected using LipofecTACE (Gibco BRL/
Life Sciences) with three plasmids encoding the P, NP,
and L bPIV3 genes and a CAT minigenome flanked by
the bPIV3 leader and trailer. The plasmids were trans-
fected using the following amounts of DNA: NP/pCITE
(200 ng), P/pCITE (200 ng), L/pCITE (50–300 ng), and
bPIV3/CAT (500 ng). The cells were transfected for 5 h at
33°C. Following the removal of the transfection mix, the
incubation of the cells was continued at 33, 37, or 39°C.
Forty hours posttransfection, the cells were lysed and
analyzed for the amount of CAT protein produced by CAT
ELISAs (Roche Molecular).
Growth curves
Vero cells were grown to 90% confluence and infected
at an m.o.i. of 0.01 PFU/cell with bPIV3, r-bPIV3, or
r-bPIV3(I). The infected monolayers were incubated at 37,
39, and 40°C. At 0, 24, 48, 72, and 96 h postinfection,
cells and media were harvested together and stored at
280°C. Virus titers for each time point harvest were
determined by TCID50 assay in Vero cells.
Efficiency of plaque formation assay
Plaque assays were carried out on Vero cells with
bPIV3, r-bPIV3, r-bPIV3(I), and bovine/human PIV3(I). The
infected monolayers were incubated at 37, 38, 39, and
40°C. Four days postinfection, the infected monolayers
were immunostained using bPIV3-specific antisera
(VMRD) or hPIV3-specific monoclonal antibodies
(Chemicon). The plaques were quantified and titers at
the different temperatures were determined to identify
the shut-off temperatures of the viruses.
Small animal studies
Five-week-old Syrian golden hamsters (four animals
per group) were infected intranasally with 5 3 105 PFU of
PIV3, r-bPIV3, r-bPIV3(I), or bovine/human PIV3(I) in a
00 ml volume. The three different groups were main-
ained separately in microisolator cages. Four days
ostinfection, the nasal turbinates and lungs of the ani-
als were harvested, homogenized, and stored at
80°C. The titers of virus present in the tissues was
etermined by TCID50 assays in Vero cells. SACKNOWLEDGMENTS
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